Labiotech - Podcast Details

Shows

Beyond Biotech - the podcast from Labiotech Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy playRaising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’?This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that b...

2025-10-0344 min

Beyond Biotech - the podcast from Labiotech BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this yearPartnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder that the biggest partnering events attract hundreds of innovators and thousands of attendees.One of the largest industry partnering events in Europe is BIOSPAIN. This year BIOSPAIN will take place in Barcelona, and the Catalan city will welcome participants from more than 40 countries for three days of exhibitions, partnering meetings, and presentations from industry leaders. Labiotech wi...

2025-09-1944 min

Beyond Biotech - the podcast from Labiotech [Rebroadcast] The power of natural killer cellsWhile our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D.The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.Al...

2024-12-2728 min

Beyond Biotech - the podcast from Labiotech [Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNAWhile our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA.The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversible, and how it can treat...

2024-08-0932 min

Beyond Biotech - the podcast from Labiotech [Rebroadcast] How does AI assist drug discovery?While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer!Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. The research will test 15 to 20 undruggable targets - but are they undruggable? And...

2024-08-0238 min

Beyond Biotech - the podcast from Labiotech Overcoming clinical trial challengesThis week, we have a conversation about clinical trial design with Gen Li, the president and founder of Phesi, a global provider of patient-centric data analysis. Earlier this year, Phesi’s global analysis of all clinical trials conducted in 2023 revealed that more than a quarter (28%) of trials were cancelled during phase II – above the average attrition rate of 20% before 2020. 00:39-01:31: About Phesi01:31-01:49: Is your database global?01:49-03:08: How successful are the different phases of clinical trials?03:08-04:29: What are the biggest challenges for clinical trials currently?04:29-06:23: Are cl...

2024-04-2626 min

Beyond Biotech - the podcast from Labiotech The biotech investment landscape in 2024RTW is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies, rare diseases, targeted oncological, cardiovascular, and neurological disorders, and more.To get an overview of what’s happening in financing for biotech companies currently, we had a conversation with Stephanie Sirota, chief business officer of RTW Investments.01:11-04:18: About RTW Investments04:18-06:45: Wha...

2024-04-1928 min

Beyond Biotech - the podcast from Labiotech Redefining chronic pain treatmentDoloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain.The Doloromics pipeline is built upon a proprietary discovery and validation platform DOLOReS. Jackson Brougher, chief scientific officer and co-founder of Doloromics, is our guest on this week’s Beyond Biotech podcast.00:46-04:41: About Doloromics04:41-07:09: What is chronic pain?07:09-08:30: How cha...

2024-04-1235 min

Beyond Biotech - the podcast from Labiotech Colossal aims to bring back mammoth by 2028Based in Austin, Texas, biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems. Its mission is to use CRISPR technology to bring back extinct animals, such as the mammoth, the thylacine, and the dodo.Since DNA was recovered in 2021 from mammoths frozen in the Arctic tundra, the company has been working on splicing bits of the recovered DNA into the genome of its closest relative, the Asian elephant, as it shares 99.6% of its DNA. Ben Lamm, co-founder and CE...

2024-04-0538 min

Beyond Biotech - the podcast from Labiotech New treatments being developed for schizophreniaIt would appear that 2024 is shaping up to be a big year for the development of treatments for schizophrenia, with several clinical trials under way.Recently, Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) announced a global collaboration and exclusive option-to-license agreement. This is to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, a novel G protein-coupled receptor (GPCR) target. The goal is to improve patient outcomes by addressing the positive, negative, and cognitive symptoms of schizophrenia.Clíona MacSweeney, Sosei Heptares’ GPR52 program leader, spoke with us about that...

2024-03-2225 min

Beyond Biotech - the podcast from Labiotech Reformulating psychedelics for neurodegenerative diseasesThere is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. 00:52-04:09: About Terran Biosciences04:09-06:03: What are the challenges of using psychedelics?06:03-07:32: Is there still a stigma attached to use of psychedelics? 07:32-11:45: How do psyc...

2024-03-1541 min

Beyond Biotech - the podcast from Labiotech How AI immune system mapping can boost drug discoveryImmunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this week’s conversation, Noam Solomon, CEO and co-founder of Immunai, covers the data gap in drug discovery and how machine learning (ML) can solve it, how to de-risk early-stage drug discovery, predictions for AI, and more....

2024-03-0828 min

Beyond Biotech - the podcast from Labiotech Is Tome writing the final chapter in genomic medicine?Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), which it says represents the final chapter in genomic medicines. We discussed the company’s formation and approach with the CEO and president of Tome, Rahul Kakkar. 00:45-04:30: About Tome Biosciences04:30-05:37: Is there still a role for CRISPR-Cas9?05:37-07:41: Raising funds for Tome07:41-11:15: What are the benefits of PGI?11:15-12:54: How...

2024-03-0133 min

Beyond Biotech - the podcast from Labiotech Transforming treatments for epilepsyAfter decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation. One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the tide. Rapport creates precision neuromedicines that act only in the brain regions where disease originates, avoiding the side effects that affect many of today’s treatments.This week, we have a conversation with Rapport CEO Abe Ceesay...

2024-02-2341 min

Beyond Biotech - the podcast from Labiotech How does AI assist drug discovery?Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time.A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process?This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a w...

2024-02-1638 min

Beyond Biotech - the podcast from Labiotech Biosimilars and what’s new in cell and gene therapiesThis week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and what’s new at Advanced Therapies Week.00:40-02:30: About Cardinal Health02:30-05:12: What is Cardinal Health’s role in industry?05:12-06:11: What are the challenges of logistics?06:11-07:20: How important is innovation to Cardinal Health?07:20-12:26: How can Cardinal Health help to reduce costs?12:26-13:08: Keeping up with global healthcare13...

2024-02-0937 min

Beyond Biotech - the podcast from Labiotech BioSenic developing severe knee osteoarthritis treatmentBioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA). This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco. 00:52-03:19: About Bio...

2024-02-0231 min

Beyond Biotech - the podcast from Labiotech Boosting fertility by changing the vaginal microbiomeFreya Biosciences is a clinical-stage biotech company dedicated to reimagining women's health and redefining fertility for those previously deprived of options. With a focus on microbial immunotherapies, Freya addresses immune drivers underlying a range of reproductive health conditions.The company recently received $38 million Series A financing to advance the clinical development of its lead drug candidate, an investigational vaginal microbial immunotherapeutic. The treatment is to address infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive technology (ART). This week’s conversation is with Freya chie...

2024-01-2632 min

Beyond Biotech - the podcast from Labiotech Epic Bio - gene editing without cutting DNAEpic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR.01:15-02:51: Dr Xi’s background02:51-05:11: The beginning of Epic Bio

2024-01-1932 min

Beyond Biotech - the podcast from Labiotech Could natural killer cells transform Alzheimer’s treatment?A US company, with its origins in South Korea, is using natural killer (NK) cells to treat Alzheimer’s disease, with remarkable results.This week, we have a conversation with Dr Paul Song, CEO of NKGen Biotech, a company with its sights set on changing the Alzheimer’s treatment landscape.00:58-02:55: About NKGen Biotech 02:56-05:39: Why is Alzheimer’s so challenging to treat? 05:39-07:28: Are there other treatments making a difference? 07:28-13:47: What is NKGen Biotech’s approach to treating Alzheimer’s? 13:47-15:38: Can you treat multiple conditions at the same time...

2024-01-1228 min

Beyond Biotech - the podcast from Labiotech Gene editing in the microbiome to treat acneEligo Bioscience is a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome. Its first target is moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population.This week, we talk to Xavier Duportet, CEO of Eligo Bioscience, as the company looks to head to the clinic with its acne vulgaris treatment. 00:53-02:42: About Eligo Bioscience 02:42-06:07: How are you creating a new class of transformative genetic medicine? 06:08-10:07: How important is the microbiome? 10:07-11:48: How do yo...

2024-01-0529 min

Beyond Biotech - the podcast from Labiotech Tackling challenging diseases with vaccinesVaxxinity, Inc. is a U.S.-based biotechnology company looking to develop vaccines for several hard-to-treat diseases such as Alzheimer’s and Parkinson’s. The company is pioneering a new class of medicines through its proprietary technology platform, which has enabled the innovation of novel synthetic peptide immunotherapy candidates to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. In this week’s podcast, the company’s CEO, Mei Mei Hu, tells us about its work, and the aim of democratizing healthcare acr...

2023-12-1525 min

Beyond Biotech - the podcast from Labiotech Using worms to treat diseasesIs there a connection between worms being eradicated from the gut in the early 20th Century and an increase in allergies and autoimmune disease? This week, we have a conversation with Holoclara CEO Andrea Choe, who not only believes there is a connection, but also sees secretions from worms as a way to tackle such diseases. 01:31-06:05: About Holoclara 06:06-08:26: From discovery to setting up a company 08:26-10:40: Was this a symbiotic relationship? 10:40-12:30: As we are losing species for a variety of...

2023-12-0821 min

Beyond Biotech - the podcast from Labiotech Ipsen advances liver disease treatmentJennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen. On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.00:56-00:49: Background information 01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease? 03:21-03:50: How rare is PBC? 03:50-04:45: How easy is PBC diagnosis? 04:45-05:45: What are the current treatments for the condition? 05:45-07:22: What are the challenges to innovation? 07:22-08:27...

2023-12-0121 min

Beyond Biotech - the podcast from Labiotech New class of small molecule therapeutics introducedOn this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.00:45-01:06: About Gate Bioscience 01:06-02:09: What are disease-causing extracellular proteins?02:09-04:44: How have diseases caused by extracellular proteins been treated in the past? 04:44-05:47: Have there been diseases that haven’t been addressed? 05:47-07:05: Tackling the different issues created by extracellular proteins 07:05-09:41: What are molecular gates? 09:41-12:56: How does your tec...

2023-11-2426 min

Beyond Biotech - the podcast from Labiotech How to make vaccines affordableAmong other things, UK-headquartered company Phenotypeca has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries to reduce the costs of vaccines.The company’s CEO, Johnny Cordiner, and research and development director, Professor Ed Louis, tell us about the work, as well as the company and its other projects.01:01-11:57: About Phenotypeca 11:57-14:04: What is recombinant protein technology? 14:04-16:39: What are the issues around the cost of albumin? 16:39-20:48: How can you help improve af...

2023-11-1740 min

Beyond Biotech - the podcast from Labiotech Mending a broken heart with biotechFrench company CellProthera has seen some remarkable results treating people who have had a heart attack. On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works.01:00-03:29: About CellProthera03:30-06:30: What are ProtheraCytes?06:30-09:02: Is this a cure?09:02-10:24: Is prevention the best option?10:25-11:49: Is this therapy useful to treat other conditions?11:50-13:55: How quickly do you need to treat a patient?13:56-16:39: The field of regenerative thera...

2023-11-1029 min

Beyond Biotech - the podcast from Labiotech How quantum computing can accelerate drug discoveryOn today’s podcast, Jean-Philip Piquemal, the chief scientific officer and co-founder of Qubit Pharmaceuticals, explains how the company’s Atlas platform is leading the way to more effective and safer drugs.00:54-01:52: The history of Qubit Pharmaceuticals01:52-04:04: What is the Atlas software?04:04-05:18: Failing quickly is the key05:19-06:53: What are digital twins?06:54-09:00: Improving safety, reducing costs, and boosting drug discovery09:00-10:44: Areas of interest10:44-13:21: Recent successes

2023-11-0328 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 69 – improving access to cell and gene therapyThis week, our guest on the podcast is Jason C. Foster, CEO of Ori Biotech.Ori is a London, U.K. and New Jersey, U.S. based manufacturing technology company pioneering flexible process discovery with translation and scalable commercialization of cell and gene therapies (CGT). Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve qu...

2023-10-2737 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 68 – rejuvenation with stem cellsThis week, our guest on the podcast is Mark Kotter, founder of newly-created company clock.bio.clock.bio, a sister company to bit.bio, which Kotter also founded and is the CEO of, aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cells (hiPSCs).These hiPSCs have the ability not only to stay young but also to rejuvenate when forced to age.Clock.bio’s approach is to harness this power of ‘resetting the cloc...

2023-10-2029 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 67 – natural killer cellsThis week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiv...

2023-10-1328 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 66 – treating rare diseases with tRNACompared to the smallest mRNA molecule, which is 300 nucleotides long, the largest transfer RNAs (tRNA) is less than a third of the size at 76 nucleotides. Scientists at Alltrna are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic mutation. This year, Alltrna presented at ASGCT the first demonstration that an engineered, modified tRNA could recognize and correct, in vivo, a flawed mRNA instruction no matter where it occurred in the genome.Alltrna, which was founded in 2018 b...

2023-10-0632 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 65 – Disease X and pandemic preparednessDisease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 vaccine development program team to the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Bennett is Moderna’s senior director of vaccine access and partn...

2023-09-2943 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 64 – Precision immuno-oncology therapiesDespite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response to existing therapies. In response to this critical challenge, Portage Biotech is on a mission to expand the number of patients who derive long-term benefits from immunotherapies. Portage Biotech is advancing a portfolio of novel precision immuno-oncology therapies, including invariant natural killer T-cell (iNKT) engagers, designed to correct the tumor microenvironment and enable the body to recognize and attack tumors, and next-generation adenosine inhibitors for a variety of...

2023-09-2238 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 63 – Tackling cancer with STRIsThis week’s podcast is sponsored by Vetter.On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics.eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converg...

2023-09-1533 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 62 – cytokine-based drugsAs September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) for targeted and safer delivery. Cue Biopharma is a standout in this field, harnessing nature’s ‘cues’ to selectively activate the immune system against cancer. Their approach overcomes IL-2’s narrow therapeutic window by directing IL-2 delivery specifically to cancer cells, targeting only disease...

2023-09-0833 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 61 - Blood Cancer Awareness MonthOn this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed's CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers.One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which is often associated with high toxicity and limited duration of response. Most other approaches to treating hematologic tumors target the adaptive immune system, neglecting the importance of innate immunity. However, harnessing the body’s first line of response could be an impo...

2023-09-0124 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 60 – The cost of researchOn this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology.Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors, published in Jama Network Open, looked at 16 inhibitors of IGF-1R, in 183 clinical trials involving more than 12,000 patients. None of the agents received approval for clinical use in...

2023-08-2533 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 59 – World Lung Cancer DaySince its inception in 2012, World Lung Cancer Day has been observed every year on August 1 in order to raise awareness of lung cancer issues and magnify the need for more lung cancer research funding.Around a quarter of a million people in the US alone will be diagnosed with some form of lung cancer in 2023. And more than 125,000 people in the US will die from the disease. And another pretty awful stat is that one in 16 men and one in 17 women will be diagnosed with lung cancer, which kills three times as many people as breast cancer...

2023-08-1819 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 58: PepteinsTo learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a challenge for manufacturing, yet exert a high biological activity, wherefore they play an increasing role as innovative molecules in a range of industries, including animal and human health. To date, peptein production via chemical synthesis or recombinant ap...

2023-08-1119 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech 57: Group B Strep2:02 Labiotech.eu news2:51 MinervaX To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due to the global burden and no current mechanism for preventing this invasive GBS disease available. There is an urgent need for a vaccine to prevent GBS which has a wel...

2023-08-0430 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 56: BaseLaunch2;00 Labiotech news3:36 BaseLaunchIn today's episode, we have a conversation with Stephan Emmerth, director business development and operations at biotech startup incubator BaseLaunch, and Sai Reddy, an entrepreneur well versed in the highs and lows of the biotech startup journey. The discussion includes BaseLaunch’s approach to empowering early-stage biotech entrepreneurs with not just financing, but also the necessary tools for success, from team-building to IP licensing. Emmerth and Reddy offer their perspectives on the realities of building a biotech startup, the perfect time to transition from a lab to...

2023-07-2835 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 55: Inflammasomes1:54 Labiotech news3:48 NodTheraThis week, we’re talking about inflammasome inhibitors with Alan Watt, CEO of NodThera.The company recently announced it is the first to show a reduction in neuroinflammation with an inflammasome inhibitor.NodThera announced positive initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF).NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases...

2023-07-2033 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech 541:24 Labiotech news3:45 TolerogenixXTolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. MIC treatment is a personalized cell therapy approach modulating the immune system via a novel mode of action to achieve a specific and sustained immune tolerance. It can not only be applied to transplant recipients, but also to patients with autoimmune diseases such as systemic lup...

2023-07-1427 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 53: Antibody-drug conjugates2:55 Labiotech news4:27 Mablink BioscienceOn the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining pharmacological properties and tolerability.The company recently announced the appointment of Dr...

2023-07-0726 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 52: Antiphospholipid syndrome2:38 Labiotech news4:23 APSFA20:59 University of MichiganJune is Antiphospholipid Syndrome (APS) Awareness Month. APS is a rare autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. There are two known forms. APS may occur in people with systemic lupus erythematosus, other autoimmune disease, or in otherwise healthy individuals.APS is also referred to as APLS or APLA in the U.S., and formerly Hughes Syndrome or Sticky Blood in the U.K.

2023-06-3043 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 511:13 Labiotech news3:09 Lund Spring Symposium27:36 SapientSapientSapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small molecule biomarker profiling. Its platform combines next-generation mass spectrometry technologies capable of assaying tens of thousands of small molecule biomarkers in human biosamples, advanced biocomputational learning, and a proprietary Human Biology Database with extensive data from several hundred thousand biosamples. Together these approaches enable rapid discovery and validation of circulating biomarkers of health, disease, and drug responsiveness at unprecedented spee...

2023-06-2354 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 50: cell and gene therapy2:45 Labiotech news4:58 Orgenesis22:35 CellProthera38:22 Terumo Blood and Cell Technologies52:02 BioSenicThe International Society for Cell & Gene Therapy (ISCT), the global society of more than 3,000 members dedicated to the translation of cell and gene therapies (CGT) into safe and effective treatments to improve patient lives, recently hosted the largest translation-focused event connecting academic, regulatory and industry experts from around the world to collaborate and find tangible solutions to the most critical issues affecting the development of advanced therapies.The event took place in Paris, France.The ISCT 2023 Translational Pathway Program fe...

2023-06-161h 09

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 491:24 Labiotech news3:40 BC PlatformsA conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma.The acquisition expands BCP’s global service offering for accelerating the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the field of RWD through the BC Platform technology.4Pharma (HQ Turku, Finland and Lund, Sweden) was founded more than 20 years ago, and has collaborations with around 70 clients in the Nordics, Central Europe, and the U.S. The company has developed expertise in a...

2023-06-0925 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 481:18 Labiotech news3:37 BioInventBioInvent International AB, a Swedish biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, recently announced positive phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors.BioInvent currently has four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both ta...

2023-06-0226 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 471:33 Labiotech news3:31 Daiichi Sankyo/AstraZenecaThe companies Daiichi Sankyo and AstraZeneca have worked together for several years.This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca.On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining forces to bring new oncology medicines into clinical practice. In March 2019, AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and com...

2023-05-2625 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 46: International Clinical Trials Day4:26 Labiotech news6:36 Medidata21:43 Bill & Melinda Gates Research InstituteThis week’s podcast is sponsored by Jubilant Biosys.May 20 is International Clinical Trials Day.ECRIN, the European Clinical Research Infrastructure Network, is a not-for-profit organization that supports the conduct of multinational clinical trials in Europe. Based in Paris, France, the organization launched International Clinical Trials Day (ICTD) in 2005 to commemorate the day when James Lind started his clinical trial on scurvy in 1747, on May 20.ECRIN is hosting an event, both in-person and online, on Monday, May 23, called Decentralised Clini...

2023-05-1946 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 45: International MPS Awareness DayThis week’s podcast is sponsored by Quantoom.International MPS Awareness DayMay is the big month when it comes to awareness - there are almost 100 awareness months, weeks, and days being marked.Some of these are well known conditions. Others, however, are less prominent.International MPS (mucopolysaccharidosis) Awareness Day takes place on May 15.According to the National MPS Society in the U.S., mucopolysaccharidosis (MPS) and mucolipidosis (ML) are genetic lysosomal storage diseases (LSD) caused by the body’s inability to p...

2023-05-1226 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 443:32 Labiotech news5:33 Lupus interviewThis week’s podcast is sponsored by Lonza.May is Lupus Awareness Month, and to talk about lupus with us this week on the podcast are Katherine Tran, senior global market development & marketing manager of the proteomics division at SCIEX, and Allan Stensballe, associate professor, Department of Health Science and Technology and associate professor, The Faculty of Medicine, at Aalborg Universitet in Denmark.Each May, The Lupus Foundation of America gathers the lupus community to make lupus visible.Lupus is a chronic autoimmune disease wher...

2023-05-0535 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 432:13 Labiotech news5:17 bit.bioThis week’s podcast is sponsored by Scientist.com.The mainstream news in the past couple of months has picked up on artificial intelligence (AI). Not so much its uses, more the potential for conflict and fears over AI developing too quickly, or ‘taking over humanity.’Debates have sprung up around deepfakes, ChatGPT, and other AI technologies, and there are concerns over how new technology will impact our everyday lives. The debate covers ethics, regulations, law, education; in fact AI and the future s...

2023-04-2831 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 422:05 Labiotech news3:32 MEET2WIN9:38 Lund Spring Symposium19:31 MerckThis week, we’re talking about the upcoming Lund Spring Symposium with Claes Wahlestedt, Leonard M. Miller professor and director of the Center for Therapeutic Innovation (CTI) and associate dean for therapeutic innovation at the University of Miami Miller School of Medicine; about Meet2Win with Lucia Robert, CEO of MATWIN which stages the event; and then an interview with two people, Andrew Clutterbuck, associate director MSAT EMEA and Mark Peacock, director, technical applications, from Merck.This week’s podcast is spons...

2023-04-2132 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 41: Sarcoidosis1:44 Labiotech news3:27 MolecureThis week, to coincide with World Sarcoidosis Day, April 13, we talk about sarcoidosis with Marcin Szumowski, CEO and president of the management board of Molecure. World Sarcoidosis DayAs part of Sarcoidosis Month, which is marked each April, World Sarcoidosis Day is on April 13. But what is sarcoidosis?The Foundation for Sarcoidosis Research explains that it is an inflammatory disease characterized by the formation of granulomas—or small clumps of inflammatory cells—in one or more organs of the body. When the immu...

2023-04-1425 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 40: Antibody drug conjugates3:13 Nectin Therapeutics26:47 ImmunomeThis episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific officer of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome.This episode of the podcast is sponsored by PHTA.ImmunomeImmunome’s Discovery Engine leverages the information stored in memory B cells to guide the discovery of first-in-class antibody therapeutics directed at potentially novel targets in oncology and other areas. Immunome’s research has revealed - and continues to unveil...

2023-03-3143 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 39: World Tuberculosis Day2:57 Labiotech.eu news4:17 PBD Biotech14:52 AAHI29:36 TB AllianceMarch 24 is World Tuberculosis Day. To mark the occasion, we have conversations with Christopher Fox, senior vice president, formulations, at the Access to Advanced Health Institute; TB Alliance CEO Mel Spigelman; and Jane Theaker, CEO of PBD Biotech.This episode of the podcast is sponsored by Samplix.World Tuberculosis DayTuberculosis is a leading infectious disease. According to the WHO, 10.6 million people became ill with the disease in 2021, a...

2023-03-2454 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 38: Hello Tomorrow Global Summit1:27 Labiotech.eu news2:38 Allogenica12:06 Helex15:51 FreezeM19:55 MediSieveThe Hello Tomorrow Global Summit took place in Paris last week (March 8-10), and we feature interviews with four of the participants.Our guests this week are: FreezeM CEO and co-founder, Dr. Yuval Gilad; Allogenica CEO and co-founder Inna Menkova; George Frodsham, founder and CEO of MediSieve; and Poulami Chaudhuri, co-founder, and CEO of Helex Bio.Hello TomorrowThe 8th edition of the Hello Tomorrow Global Summit 2023 welcomed more than 3,000 people to the forefront of deep tech. There...

2023-03-1735 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine 1:19 Labiotech.eu news2:32 Biomedical Research & Bio-Products12:15 Model N21:39 Institute of Clinical MedicineThis week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products.The next breakthrough in cancer treatment?In our body, we have an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK (n...

2023-03-0935 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 36: Bio-Europe Spring and Cellular Origins1:41 Labiotech.eu news3:41 Cellular Origins20:17 Bio-Europe SpringTwo of the interviews on the podcast today are related to Bio-Europe Spring. There are conversations with Rosie Bernard, senior director, production and content strategy for EBD Group EU, with an overview of the event, and also Jordan Stillman, project manager, partnering services at EBD Group. We also have a chat with Cellular Origins' CEO Edwin Stone. Cellular OriginsCellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addr...

2023-03-0344 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 35: Rare Disease Day0:58 Labiotech.eu news2:37 Replay23:45 Azafaros39:39 GRO BiosciencesAs February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO Biosciences; Stefano Portolano, chief executive officer, Azafaros; and from Replay, Adrian Woolfson, executive chairman, president, and co-founder, and Lachlan MacKinnon, CEO and co-founder.Rare Disease DayTaking place on February 28 each year, the event raises awareness and looks to generate change for the 300 million people worldwide living with a rare disease, as...

2023-02-241h 01

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics1:25 Labiotech.eu news3:02 GPCR Therapeutics22:16 eClinical Solutions31:04 Orbsen TherapeuticsThis week, our guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president and CSO of GPCR Therapeutics; and Larry A Couture, CEO of Orbsen Therapeutics.GPCR Therapeutics launches multiple myeloma trial GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, recently started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in mo...

2023-02-1758 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4BaseBio1:10 Labiotech.eu news2:50 Innovation Agency Lithuania25:25 Astellas Pharma34:37 4basebioThis week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas.4basebio4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in the design, manufacture and supply of application-specific synthetic DNA or mRNA, as well as targeted non-viral vectors for the delivery of nucleic acid payloads, for u...

2023-02-1045 min

Beyond Biotech - the podcast from Labiotech Talking about Alzheimer's disease: current drugs, clinical trials, and the pipelineSometimes, there’s an interview that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer look at Alzheimer’s disease with a conversation about current drugs, clinical trials, and the pipeline.Our guest is Sharon L. Rogers, CEO of the biotech AmyriAD Therapeutics.SponsorInterested in sponsoring one or more episodes of the pod...

2023-02-0946 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine01:38 Labiotech.eu news03:18 OncoHost18:13 Enterome41:04 TrakCel55:51 Cancer Research Horizons/TurbineOur guests are Ofer Sharon, CEO of OncoHost; Matthew Lakelin, co-founder, TrakCel; Pierre Belichard, CEO of Enterome; and Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons and Daniel Veres, chief science officer and co-founder, Turbine.World Cancer DayFebruary 4 is World Cancer Day. This year, the theme is Close the Gap. For the podcast this week, we feature four interviews related to cancer.TrakCelTrakCel is...

2023-02-031h 11

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 31: Orgenesis, Phacilitate, Terumo, University of Birmingham, VIVEBiotech01:22 Labiotech.eu news03:03 Phacilitate/Advanced Therapies Week14:15 Orgenesis25:18 Terumo31:47 VIVEBiotech38:33 University of BirminghamPhacilitate’s Advanced Therapies Week took place last week in Miami Beach, Florida.This week, we speak with the organizers, as well as some of the companies in attendance.Our guests are Kim Barnes, EVP, Phacilitate; Kathie Schneider, director and global commercial lead at Terumo; Vered Caplan, CEO, Orgenesis; Ivan Wall, head of the Centre for Advanced Therapies Manufacturing Training, University of Birmingham; and Natalia Elizalde, business development director, VIVEBiotech.Phacilitate...

2023-01-2748 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics02:29 Labiotech.eu news04:11 C2i Genomics22:31 Advanced Therapies Congress31:37 BioAlps47:29 Bionter54:06 JLLThe guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps.We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL.This week’s podcast is sponsored by Bionter, a Swiss-based premier supplier of analytical testing solutions to support Pharma companies to br...

2023-01-201h 00

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 29: Janssen, Knowledge Gate1:03 Labiotech.eu news2:34 Knowledge Gate10:59 Janssen Scientific AffairsThis week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs.Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patientsThe Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the...

2023-01-1229 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals2:18 Labiotech.eu news3: 46 Mainz Biomed19:14 NewronThis week, we have two guests. We have conversations with Newron Pharmaceuticals' CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler.Mainz Biomed Provides Year-End 2022 Corporate ReviewMainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022.The company launched its U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomed’s mRNA biomarkers in ide...

2023-01-0635 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 27: Cradle, Rani Therapeutics1:37 Labiotech.eu news3:34 Cradle19:47 Rani TherapeuticsThis week, we have two guests. We have conversations with Talat Imran, CEO of Rani Therapeutics; and Stef van Grieken, CEO and co-founder of Cradle.Rani Therapeutics - aiming to remove the pain of needlesRani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being...

2022-12-2338 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson2:19 Labiotech.eu news4:37 CellCentric12:21 MicrofluidX29:12 Potter ClarksonThis week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson.MicrofluidX raises £3.3M to develop advanced therapy manufacturing platformMicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million ($4 million) of secured investments, bringing the company’s total funding to date to £7 million ($8.5 million). MFX’s next generation platform, the Cyto Engine, addresses the need...

2022-12-1647 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene2:33 Labiotech.eu news5:03 Humacyte23:01 Transgene37:21 Center for Global Development54:32 JLLThis week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance.We also have our weekly commentary from Travis McCready at JLL.HumacyteThe ongoing war in Ukraine continues to present significant challenges for frontline hospitals in treating...

2022-12-091h 02

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech2:40 Labiotech.eu news4:58 SOTIO Biotech13:43 Eversana19:37 Carl Borrebaeck36:42 Concarlo TherapeuticsThis week, we have four interviews: Franjo Hanzl, vice president commercial development Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, chief business officer at SOTIO Biotech; and Carl Borrebaeck, chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in Sweden.Concarlo TherapeuticsConcarlo Therapeutics is a U.S.-based preclinical-stage precision-medicine oncology company. It is developing a novel therapy for drug-resistant...

2022-11-2557 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics1:45 Labiotech.eu news4:02 PsychoGenics20:56 Destiny Pharma36:30 QureTech Bio54:41 AiCuris70:45 JLLThis week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio.We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Next week, we wi...

2022-11-181h 17

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 22: PacBio, Sierra Space1:32 Labiotech.eu news4:02 PacBio34:02 Sierra Space57:12 JLLThis week, we have two longer interviews. We have conversations with Neil Ward, VP of PacBio EMEA, and Marc Giulianotti, senior manager in space biomanufacturing at Sierra Space.We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Sierra Space and UC San Diego to develop first stem cell research institute in spaceSierra Space and University of California San Diego, one of the world’s top 15 research universities and a lea...

2022-11-111h 04

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation1:41 Labiotech.eu news4:17 Longevity Science Foundation23:07 HTID35:56 CanSinoBio54:47 JLLThis week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation's CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. HealthTech Innovation Days brings European healthtech ecosystem togetherThe 4th...

2022-11-041h 01

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 20: BioWin, eTherapeutics, CMT Research Foundation5:33 e-therapeutics21:25 BioWin 32:46 CMT Research Foundation57:47 JLLThis week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company JLL, with Robert Coughlin, managing director and New England Life Science Practice Group lead. CMT Research Foundation supports SamsaraThe CMT Research Foundation (CMTRF), a non...

2022-10-281h 02

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 19: Bone Health Technologies, Immutep, TAU Systems2:22 Labiotech.eu news4:53 TAU Systems21:54 Bone Health Technologies 33:26 Immutep44:36 JLLThis week, we have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidateImmutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pe...

2022-10-2151 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals2:08 Labiotech.eu news4:42 Faron Pharmaceuticals15:22 BiotechX20:13 Cultivated Biosciences26:26 EPFLThis week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in NovemberBiotechX, an event staged by Terrapinn, is set to open its doors next month.F...

2022-10-1446 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 17: BIO-Europe, National Hemophilia Foundation2:09 Labiotech.eu news4:16 BIO-Europe (biosaxony)13:54 BIO-Europe (EBD Group EU)28:25 National Hemophilia Foundation44:40 JLLThis week, we have three interviews. Our guests are: Pam Putz, managing director of EBD Group EU; André Hofmann, CEO of biosaxony; and Kevin Mills, chief scientific officer at the National Hemophilia Foundation and Teri Willey, managing director of the National Hemophilia Foundation’s Pathway to Cures. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. BIO-Europe set to start in LeipzigBIO-Europe is retur...

2022-10-0750 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 16: Adocia, Omnio, Phenomix Sciences, Tridek-One3:00 News5:04 Omnio14:01 Adocia24:28 Tridek-One29:49 Phenomix Sciences47:27 JLLThis week, we have four guests: Olivier Soula, deputy-CEO and director of R&D at Adocia; Ulrika Norin, CEO of Omnio; Mark Bagnall, CEO of Phenomix Sciences; and Laurence de Schoulepnikoff, CEO of Tridek-One.We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored by Labforward.Adocia takes steps with implants to treat type 1 diabetesFrench biopharma company Adocia has established a fir...

2022-09-3053 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed02:17 Labiotech.eu news04:59 TikoMed09:20 Pleco Therapeutics25:45 Cullinan Oncology/World Cancer Research Day44:15 JLLThis week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed.We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. This week’s podcast is sponsored by Single Use Support, the e...

2022-09-2350 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 14: NLS Days2:56 News5:42 NLS Days - overview17:42 NLS Days - NLSInvest29:35 NLS Days - AstraZeneca42:13 JLLBeyond Biotech Podcast 14: Nordic Life Science Days 2022This week’s podcast is dedicated to Nordic Life Science Days, otherwise known as NLS Days. This year’s version is an in-person event from September 28-29, at the Malmömässan in Malmö, Sweden.In our preview of NLS Days, which features sessions and fireside chats, company presentations, an exhibition, and one-on-one partnering meetings, we have interviews with managing director of NLSDays, Olivier Duchamp...

2022-09-1648 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 13: BioInnovation Institute, IASP2:32 Labiotech.eu news4:45 BioInnovation Institute20:18 IASP37:38 JLLThis week’s guests on the podcast are Bobby Soni, chief business officer at the BioInnovation Institute, and Harriet Edwards, International Association of Science Parks (IASP) media and community manager.We also have our weekly chat with global commercial real estate services company JLL, and this week it is with Travis McCready. IASP to host World Conference on Science ParksThe 39th IASP World Conference on Science Parks and Areas of Innovation is set to tak...

2022-09-0943 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 12: Gate Neurosciences, Oncolyze, 3Brain2:48 Labiotech.eu news5:22 Gate Neurosciences16:18 3Brain31:13 Oncolyze50:22 JLLThis week’s podcast guests are Mike McCully, CEO of Gate Neurosciences; Steven Evans, CEO and co-founder of Oncolyze; and Philipp Markolin, scientific marketing specialist at 3Brain.We also have our weekly chat with global commercial real estate services company JLL, and this week it’s a chat with Amber Schiada, head of life sciences research in the Americas for the company.Gate launches to develop CNS t...

2022-09-0256 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics2:15 Labiotech.eu news5:12 Phase Genomics16:44 IRB Barcelona29:37 Ilya Pharma43:00 Krystal Biotech53:54 JLLOur guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO of Phase Genomics.We also have a new weekly addition, as JLL will be joining us with a look at financial news. This week, we’re joined by Robert Coughlin, JLL managing directo...

2022-08-2658 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 10: Endpoint Health, Nevrargenics, TriastekThis week our guests on the podcast are Xianghao Zuo, deputy director of R&D at Triastek; Endpoint Health CEO Jason Springs; and Andy Whiting, CEO of Nevrargenics.2:15 News4:28 Nevrargenics22:26 Triastek37:14 Endpoint HealthTriastek and Lilly working together on 3D printing for drugsA new research collaboration between Chinese company Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine. Triastek has developed 3D printing technology to provide solutions for drug d...

2022-08-1952 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, ValnevaThis week's guests are ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva.1:40 News3:47 PTC18:32 Micropep33:01 Valneva42:12 ARCHARCH Venture Partners closes $2.97B biotech fundARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. ARCH Venture Partners is one of the large...

2022-08-1255 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKAREThis week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.News: 02:30Endogena Therapeutics 5:10eureKARE 21:00Deep Science Ventures 33:46Biotech Growth Trust 47:44Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP)....

2022-08-051h 00

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 7: World Hepatitis DayThis week's podcast features three interviews related to hepatitis.Our guests are Ahmed Elsharkawy, consultant transplant hepatologist and honorary senior clinical lecturer at the University of Birmingham in the UK; Ziv Ben-Ari, director of the Liver Diseases Center at the Sheba Medical Center in Israel, and James McIlroy, chief executive officer at EnteroBiotix.World Hepatitis DayTaking place on July 28 every year, World Hepatitis Day unites the world under a single theme to raise awareness of the global burden of viral hepatitis with the intention of influencing real change...

2022-07-2945 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg PharmaOn this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify.Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.Biopharma company Mogrify Limited, and Japanese regenerative medicine fi...

2022-07-2246 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 4: CorePath, Rensselaer, VersamebThis week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

2022-07-1446 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 5: ANeuroTech, ISA Pharmaceuticals, Life LengthThis week’s guests are Erik Buntinx, CEO and founder of ANeuroTech; Stephen J. Matlin, CEO of Life Length; and Kees Melief, chief scientific officer at ISA Pharmaceuticals.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to ou...

2022-07-1458 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, UnileverOn this week’s Labiotech.eu podcast, we have three guests.We had conversations with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Conne...

2022-07-0141 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech podcast 2: Asabys, Asebio, MOA FoodtechThis week’s podcast is dedicated to Spain.We have conversations with bioindustry association AseBio’s CEO, Ion Arocena; Clara Campàs, managing partner and co-founder of venture capital company Asabys, and Susana Sánchez Gómez, co-founder and chief scientific officer at MOA Foodtech.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear...

2022-06-2439 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech 01: June 17, 2022Three interviews on the show this week, with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two guests from Forbion - Sander Slootweg, managing partner, and Dirk Kersten, general partner. And a quick look at the news from the past seven days.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to h...

2022-06-1748 min

Beyond Biotech - the podcast from Labiotech Beyond Biotech: PreviewA quick preview of the new, weekly podcast on what's new in the world of biotech, from Labiotech.euSponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

2022-06-1006 min

Adam Alonzi Podcast Biotech Trends with Joachim Eeckhout of Labiotech.eu Joachim is the co-founder & COO of Labiotech.eu, the leading digital media covering the European Biotech industry. It is used by over 15,000 people monthly to keep a watch on the business and innovations of biotechnologies. Join them for free and enjoy reading our stories! Take a look at his website and feel free to contact him. It will be a pleasure to talk with you about biotechnologies and entrepreneurship! http://labiotech.eu/mrna-therapies-curevac-outperformed-the-money-magnet-moderna/ Servier http://labiotech.eu/how-servier-saved-cellectis-the-french-car-t-miracle/ BioPrinting http://labiotech.eu/loreal-get-into-bio-printing-skin-for-cosmetic-tests/

2015-10-0124 min